ELITE PHARMACEUTICALS INC /NV/ Quarterly Liabilities and Equity in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly Liabilities and Equity history and growth rate from Q1 2011 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Liabilities and Equity for the quarter ending September 30, 2024 was $88.2M, a 24.7% increase year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $88.2M +$17.5M +24.7% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $87.8M +$41.3M +88.9% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $83.7M +$42.8M +105% Mar 31, 2024 10-Q 2024-11-14
Q4 2023 $74.7M +$22M +41.7% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $70.7M +$20.4M +40.5% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $46.5M -$1.61M -3.34% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $40.9M +$5.75M +16.4% Mar 31, 2023 10-K 2024-07-01
Q4 2022 $52.7M +$20.8M +65% Dec 31, 2022 10-Q 2023-02-14
Q3 2022 $50.3M +$19.7M +64.4% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $48.1M +$18.1M +60.4% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $35.1M +$8.96M +34.2% Mar 31, 2022 10-K 2023-06-29
Q4 2021 $31.9M +$3.28M +11.4% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 $30.6M +$3.02M +10.9% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $30M +$2.17M +7.8% Jun 30, 2021 10-Q 2021-08-16
Q1 2021 $26.2M +$1.23M +4.94% Mar 31, 2021 10-K 2022-06-29
Q4 2020 $28.7M +$4.58M +19% Dec 31, 2020 10-Q 2021-02-16
Q3 2020 $27.6M +$4.07M +17.3% Sep 30, 2020 10-Q 2020-11-16
Q2 2020 $27.8M +$3.54M +14.6% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 $25M +$555K +2.27% Mar 31, 2020 10-K 2021-06-14
Q4 2019 $24.1M -$2.29M -8.69% Dec 31, 2019 10-Q 2020-02-10
Q3 2019 $23.5M -$3.79M -13.9% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $24.3M -$4.21M -14.8% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 $24.4M -$6.48M -21% Mar 31, 2019 10-K 2020-06-30
Q4 2018 $26.4M -$5.7M -17.8% Dec 31, 2018 10-Q 2019-02-11
Q3 2018 $27.3M -$4.69M -14.7% Sep 30, 2018 10-Q 2018-11-09
Q2 2018 $28.5M -$5.39M -15.9% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 $30.9M -$3.43M -9.99% Mar 31, 2018 10-K 2019-06-21
Q4 2017 $32.1M -$4.13M -11.4% Dec 31, 2017 10-Q 2018-02-09
Q3 2017 $32M -$2.86M -8.19% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $33.9M +$829K +2.51% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $34.3M +$2.64M +8.33% Mar 31, 2017 10-K 2018-06-14
Q4 2016 $36.2M +$9.07M +33.4% Dec 31, 2016 10-Q 2017-02-09
Q3 2016 $34.9M +$6.17M +21.5% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 $33.1M +$3.15M +10.5% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 $31.7M +$5.75M +22.2% Mar 31, 2016 10-K 2017-06-14
Q4 2015 $27.1M +$1.43M +5.56% Dec 31, 2015 10-Q 2016-02-09
Q3 2015 $28.7M +$4.81M +20.1% Sep 30, 2015 10-Q/A 2015-12-30
Q2 2015 $29.9M +$5.94M +24.8% Jun 30, 2015 10-Q/A 2015-12-30
Q1 2015 $25.9M +$1.6M +6.59% Mar 31, 2015 10-K 2016-06-15
Q4 2014 $25.7M +$7.42M +40.6% Dec 31, 2014 10-Q 2015-02-17
Q3 2014 $23.9M +$6.48M +37.2% Sep 30, 2014 10-Q 2014-11-14
Q2 2014 $24M +$13.6M +131% Jun 30, 2014 10-Q 2014-08-14
Q1 2014 $24.3M +$13.2M +119% Mar 31, 2014 10-K 2015-06-15
Q4 2013 $18.3M +$7.91M +76.2% Dec 31, 2013 10-Q 2014-02-14
Q3 2013 $17.4M +$7.34M +72.8% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 $10.4M +$205K +2.01% Jun 30, 2013 10-Q 2013-08-14
Q1 2013 $11.1M +$813K +7.89% Mar 31, 2013 10-K 2014-06-30
Q4 2012 $10.4M +$21.9K +0.21% Dec 31, 2012 10-Q 2013-02-14
Q3 2012 $10.1M -$761K -7.02% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 $10.2M -$1.3M -11.3% Jun 30, 2012 10-Q 2012-08-14
Q1 2012 $10.3M -$1.48M -12.5% Mar 31, 2012 10-K 2013-06-21
Q4 2011 $10.3M Dec 31, 2011 10-Q 2012-02-14
Q3 2011 $10.8M Sep 30, 2011 10-Q 2011-11-14
Q2 2011 $11.5M Jun 30, 2011 10-Q/A 2011-08-19
Q1 2011 $11.8M Mar 31, 2011 10-K 2012-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.